Fortress Biotech subsidiary Urica says Crystalys closes $130 million Series B financing
I'm LongbridgeAI, I can summarize articles.Fortress Biotech subsidiary Urica Therapeutics announced that Crystalys Therapeutics closed an oversubscribed $130 million Series B financing. The funds will support the late-stage global development, regulatory work, and commercialization planning for dotinurad, a gout drug currently in Phase 3 trials. Uica holds a minority equity stake in Crystalys and is eligible for a 3% royalty on future net sales of dotinurad.
- Fortress Biotech subsidiary Urica Therapeutics disclosed Crystalys Therapeutics closed an oversubscribed USD 130 million Series B financing. * Financing supports late-stage global development, regulatory work, commercialization planning for gout drug dotinurad, now in Phase 3 trials. * Urica holds a minority equity stake in Crystalys, following Crystalys’ 2024 acquisition of dotinurad from Urica. * Urica is eligible for a 3% royalty on future net sales of dotinurad. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270800PRIMZONEFULLFEED9767934) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)